Japan America Society of Greater Philadelphia

Aging Populations:

Neurogenerative Diseases, Psychiatric Therapies

	Program Overview
	Neurodegenerative diseases such as Alzheimer’s disease and Parkinsons’ disease not only put stress on patients and their families, but also cause monumental societal problems, particularly in countries with aging populations. Both the capacity for and cost of care are serious problems today, and will grow more severe in the coming years. Japan’s demographic profile suggests that the crisis will be faced sooner than in the United States, but without a doubt, both countries will have to deal with it early in this century. In the meantime, companies in both countries are seeking diagnostic and therapeutic approaches that may serve to lessen the coming burden. The 8th Annual Philadelphia-Japan Health Sciences Dialogue, featuring distinguished leaders in the field, is designed to take stock of what is happening in Japan and the United States to address this problem.
Monday October 1, 2007
5:00 PM Registration 5:30 - 8:00 PM	Reception with Poster Presentations of Young Companies
5:00 PM Registration 5:30 - 8:00 PM	Presenters: Neuronetics Smart Biosciences Avid Radiopharmaceuticals Keisen Associates Nara Institute of Science and Technology Red Ion Medical Corporation JETRO NY Cognosci, Inc.

Tuesday October 2, 2007
8:00 AM Registration and Continental Breakfast 8:15 - 8:30 AM	Welcome Remarks
	Mr. David Briel Executive Director, Center for Direct Investment, Department of Community and Economic Development, Commonwealth of Pennsylvania

8:30 - 9:45 AM	Panel Discussion: Demographic and Economic Trends
	Moderator: Dr. Gail Wilensky Senior Fellow & Economist, Project HOPE Panelists: Dr. Robert Field Chair, Department of Heath Policy and Public Health, University of Science in Philadelphia Mr. Jean-Paul Gagnon Director, Public Policy, Sanofi Aventis Dr. Naoki Ikegami Professor and Chair, Department of Hearth Policy and Management, Keio University Dr. Richard Stefanacci Executive Director, Health Policy Institute, University of the Sciences in Philadelphia

9:45 - 10:30 AM	Diagnosis: Biochemical Markers, Cognitive Measurements, Imaging
	Presenters: Dr. Mark Cochran CEO & Executive Director, Blanchette Rockefeller NeuroSciences Institute Dr. Stephen Moelter Assistant Professor of Psychology, University of the Sciences in Philadelphia Dr. Daniel Skovronsky President and CEO, Avid Radiopharmaceuticals

10:30 - 10:45 AM	Break
10:30 - 10:45 AM
10:45 - 11:30 AM	Regulatory Trends Affecting Product Approvals and Reimbursement of New Drugs and Biologics
	Mr. Stephen Paul Mahinka Partner, Morgan Lewis & Bockius LLP Mr. Satoru Nagasaka Partner, TMI Associates

11:30 - 12:00 PM	Institutional Care and Infrastructure, Government and Charitable Support
	Speaker: Ms. Susan Brecht President, Brecht Associates, Inc.

12:00 - 12:30 PM	Beta Amyloid and Alzheimer's Disease: Cause or Result?
	Speaker: Dr. Sam Gandy Director, Farber institute for Neurosciences, Thomas Jefferson University

12:30 - 2:00 PM	Luncheon Keynote Address
	Introduction: Mr. Philip R. Hopkins Director of Research, Select Greater Philadelphia Speaker: Mr. Lonnel Coats President & COO, Eisai Inc.

2:00 - 2:15 PM	Break
2:00 - 2:15 PM
2:15 - 3:45 PM	Panel Discussion: New Products of Psychiatric Disorders Affecting the Aged
	Moderator: Dr. Steve E. Arnold Professor of Psychiatry and Neurology; Director, Section on Geriatric Psychiatry; Directory Cellular and Molecular Pathology Program, The Mahoney Institute of Neurological Sciences, University of Pennsylvania Panelists: Dr. Taro Iwamoto President and COO, Otsuka Pharmaceutical Development and Commercialization Dr. Jamie Mullen Executive Director, AstraZeneca Pharmaceuticals Ms. Charlotte E. Sibley Senior Vice President, Global Business Research and Intelligence, Shire Pharmaceuticals

3:45 - 4:00 PM	Break
3:45 - 4:00 PM
4:00 - 5:00 PM	Case Study : The Wyeth Story
	Speaker: Dr. Steve Jacobsen, Associate Director, Neuroscience Discovery, Wyeth

5:00 PM	Reception
5:00 PM